Thomas Cannell, Sesen Bio CEO
Sesen Bio pauses bladder cancer drug work, offloads eye disease antibodies to Roche
Following an FDA rejection last year, Sesen Bio announced this morning that it will be pausing development on its lead bladder cancer drug.
With the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
